KRAS and pachyonychia congenita: KRAS2 mutation was detected in 22 patients (47%) with PC and in 4 controls with CP (13%) (P < 0.002). The combination of KRAS2 and CA19.9 gave a sensitivity and specificity of 98% and 77% respectively.